Category: News

Treat the cause – not the symptoms. It’s an old phrase but Australian drug developer Nyrada (ASX: NYR) is proving this philosophy is the future of drug therapies. Nyrada develops small molecule drugs that treat the underlying causes of diseases that currently have few, if any effective therapies.

Now more than ever society relies on ultra fast, reliable and secure digital experiences. 5G Networks (ASX: 5GN) is an Australian telecom that powers every aspect of critical digital infrastructure across the nation. 

Last Wednesday at our weekly ‘Meet The CEOs’ briefing we were joined by Dr Chris Burns from Novonix Limited (ASX: NVX). Novonix is an integrated developer and supplier of high-performance materials, equipment and services for the global lithium-ion battery industry. They have operations in the USA and Canada and sales in over 14 countries. 

Credit Intelligence (CI1) is an ASX-listed fintech company experiencing tailwinds amidst the economic uncertainty of COVID-19 and a long-awaited market correction. 

Rhinomed (ASX: RNO) radically improves the way people breathe, sleep, maintain their health and take medication. The company produces a wearable nasal stent platform that reduces snoring, increases air intake and relieves congestion and allergies through essential oil formulations.

The new round of the ASX Options Trading Game is now open so make sure to create an account (or login if you already have one) to start playing for a chance to win yourself weekly cash prizes, brokerage, education and much more.

Manuka Resources, the nation’s newest gold and silver producer, has launched its IPO. The company is looking to raise between $5 to $7 million to explore and mine highly prospective tenements across its two sites in the Cobar Basin, Central NSW.

Despite the tumultuous market and economic recession, ASX-listed Spirit Telecom (ASX: ST1) grew 146% in the four months January to April, compared to the prior corresponding period. 

Conditions like dementia and Alzheimer’s disease have the most likelihood of a medical breakthrough in the next 10 years. However, at present, there are few effective treatment options. For ASX-listed Neuroscientific Biopharmaceuticals (NSB), this is a focus area that shows great commercial promise and opportunity to improve patient outcomes.

The market’s recent gains have come largely from retail investors entering the market but not everyone is convinced that this rally is real. Magellan Co-founder defended his 46% cash position this week and many others are publicly voicing concerns that the market rally is just a dead cat bounce.

Cancer treatments are changing and Prescient Therapeutics (ASX: PTX) is an Australian biotech company that is leading the way. Prescient’s PTX 100 and PTX 200 therapies have had compelling results in human clinical trials.  

The ASX Options Game has come to a close; it’s been a great Game this time around with a record number of players competing for the grand prize! 18-year old Kosta Konstant from NSW is the winner with a final portfolio of $349,533. We asked him a couple of questions about himself and his approach to trading and how he learned how to trade and he agreed to share his thoughts!